CD8A and neoplasm: We found that treatment of DKO with the anti-VISTA antibody (Supplementary Fig. S9D) resulted in a significant reduction in the tumor size/tumor weight (Fig. 6A–C) but increased in spleen weight (Fig. 6D, E) and frequency of CD8+ T cells (Supplementary Fig. S9E) without any change in the frequency of CD4+ T cells, NK cells and CD11b+ cells.